Erlotinib-induced pustular eruption.
G Ital Dermatol Venereol
; 144(1): 93-6, 2009 Feb.
Article
de En
| MEDLINE
| ID: mdl-19218915
ABSTRACT
The epidermal growth factor receptor (EGFR) inhibitor erlotinib was found to significantly improve overall survival, time to progression, and cancer-related symptoms in locally advanced or metastatic non small cell lung carcinoma (NSCLC). Unfortunately, cutaneous side effects are not rare, the most common one being a follicular acneiform eruption. As it has been observed a positive correlation between rash severity and objective tumor response, it is critical for dermatologists early distinguish it from rashes carrying a different prognosis and needing a different management.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Quinazolines
/
Éruptions acnéiformes
/
Carcinome pulmonaire non à petites cellules
/
Inhibiteurs de protéines kinases
/
Tumeurs du poumon
Type d'étude:
Prognostic_studies
Limites:
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
G Ital Dermatol Venereol
Année:
2009
Type de document:
Article
Pays d'affiliation:
Italie